Results 101 to 110 of about 21,331 (238)
BiomoleculesBTK (Bruton’s tyrosine kinase) has become a key therapeutic target across several hematologic diseases, beginning with its original use in CLL/SLL.
Andrea Duminuco +9 more
doaj +1 more source
Discovery of BTK Kinase Inhibitors as Targeted Therapeutics for B-cell Malignancies [PDF]
, 2016 B细胞恶性肿瘤（Bcellmalignancies）起源于B淋巴细胞在其生长发育的关键时期内不受控制的生长。酪氨酸激酶BTK(Bruton'styrosinekinase)是非受体酪氨酸激酶Tec家族的成员，其激活对于多种B细胞恶性肿瘤的生长和存活都至关重要。本论文采用了“以化合物为中心”的高并行筛药策略，并基于Ba/F3细胞毒性差异高通量分析筛选了实验室内部化合物库，并获得BTK靶标激酶的“Hit”化合物。之后，将“Hit”化合物进行一系列的结构优化 ...
贵甫
core
From Time‐Limited Therapy to Treatment‐Free Observation: The Evolving Role of MRD in CLL Management
European Journal of Haematology, EarlyView.ABSTRACT The integration of measurable residual disease (MRD) into the management of chronic lymphocytic leukemia (CLL) has emerged as a major advance in risk stratification and trial design, particularly in the context of time‐limited, targeted regimens.
Enrica Antonia Martino +13 more
wiley +1 more source
Bruton’s Tyrosine Kinase: A Double-Edged Sword in Cancer and Aging
Kinases and PhosphatasesBruton’s tyrosine kinase (BTK) is a key signaling molecule involved in both hematological malignancies and solid tumors. In B-cell malignancies such as chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), BTK mediates B-cell receptor ...
Zahraa Qusairy, Miran Rada
doaj +1 more source
Regional Standardization of CLL Management: Results of a Delphi Consensus Process
European Journal of Haematology, EarlyView.ABSTRACT The therapeutic landscape of chronic lymphocytic leukemia (CLL) has been profoundly transformed by the introduction of Bruton tyrosine kinase and BCL‐2 inhibitors. Despite improved survival outcomes, treatment selection remains complex, particularly in older patients with comorbidities, frailty, and increased infectious vulnerability.
Enrica Antonia Martino +22 more
wiley +1 more source
Regulation of B cell fate by chronic activity of the IgE B cell receptor. [PDF]
, 2016 IgE can trigger potent allergic responses, yet the mechanisms regulating IgE production are poorly understood. Here we reveal that IgE+ B cells are constrained by chronic activity of the IgE B cell receptor (BCR).
Allen, Christopher DC +6 more
core +1 more source
European Journal of Haematology, EarlyView.ABSTRACT Minimal residual disease (MRD) has emerged as a central biomarker in hematologic malignancies, enabling highly sensitive detection of tumor persistence beyond conventional morphologic assessment and serving as an increasingly important surrogate endpoint in clinical trials.
Santino Caserta +14 more
wiley +1 more source
Charting the NF-kB pathway interactome map [PDF]
, 2010 One of the phenomena observed in human aging is the progressive increase of a systemic inflammatory state, a condition referred to as “inflammaging”, negatively correlated with longevity. The five components of the Nuclear Factor kB (NF-kB)
Alberto Termanini +4 more
core +2 more sources
Evolving treatments for Sjögren disease: current approaches and emerging targets
Internal Medicine Journal, EarlyView.Abstract Sjögren disease (SjD) is a prevalent systemic autoimmune condition characterised by exocrine gland dysfunction, systemic inflammation and heterogeneous organ involvement. Current management remains largely symptomatic, with no approved disease‐modifying therapies available and substantial unmet clinical need. However, advances in understanding
Mansi Bhurani +3 more
wiley +1 more source
Ibrutinib inhibits platelet integrin αIIbβ3 outside-in signaling and thrombus stability but not adhesion to collagen [PDF]
, 2015 OBJECTIVE: Ibrutinib is an irreversible Bruton tyrosine kinase inhibitor approved for treatment of Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, and mantle cell lymphoma that increases the risk of bleeding among patients. Platelets from
Alexander P. Bye +6 more
core +1 more source